Thursday, March 5, 2026
3:00 PM – 4:00 PM UTC
4:00 PM – 5:00 PM CET
10:00 AM – 11:00 AM EST
Learning Objectives:
-
Enhance understanding of eye toxicity related to emerging anticancer drugs with a focus on ADCs—acute, delayed, and anticipatory types—along with their pathophysiology and variability in patient experiences
-
Emphasize the importance of proactive management and monitoring
-
Promote collaboration within multidisciplinary teams (MDTs) and discuss when and why to drive the patient to the ophthalmologist
-
Gain valuable insights into patients’ experiences to better understand the impact of eye toxicity
Agenda:
Introduction – Prof. Florian Scotté (Chair)
From Basic to Specialized Management: The Ophthalmologist Perspective – Dr. Grégoire Chevreau
Emerging Drugs, Emerging Toxicities and Eyes: Why and How Can We Anticipate During Drug Development? – Prof. Mario Mandalà
The Impact of Eye Toxicity in the Oncological Practice, Are There Guidelines? – Dr. Iphigénie Korakis
The Patient Perspective: Impact and Outcomes in the Short and Long Term – Amy Russell-Parliman (Patient Advocate)
Q & A
Speakers:
Prof. Florian Scotté
(Chair)
Dr. Grégoire Chevreau
Prof. Mario Mandalà
Dr. Iphigénie Korakis
Amy Russell-Parliman (Patient Advocate)
This webinar is made possible by an unrestricted grant from Daiichi Sankyo|Astrazeneca
